About this trial
This study seeks to compare the clinical efficacy and safety of the novel sedative Remimazolam with Dexmedetomidine in Drug-Induced Sleep Endoscopy (DISE), evaluating their performance in sedation depth stability, incidence of adverse events, and postoperative recovery time, thereby providing evidence-based guidance for sedative selection in OSA patients. Additionally, it aims to develop a model for predicting upper airway obstruction sites by analyzing Polysomnography (PSG) data with artificial intelligence, enhancing diagnostic accuracy and treatment decision-making efficiency for Obstructive Sleep Apnea (OSA) to optimize clinical management.
Eligibility criteria
Qualifiers
Patients age > 18 years old
American Society of Ansthesiologists functional class < III
Schedule to receive DISE exam for evaluation of OSAS
Disqualifiers
Patient refusal
Allergic to experimental medication
History of central nervous system diseases
History of psychiatric diseases
Trial design
Treatments tested in this trial
- Remimazolam
- Dexmedetomidine